Klinik und Poliklinik für Innere Medizin II, Kardiologie, Universitätsklinikum Regensburg, Franz-Josef-Strauss Allee 11, 93042 Regensburg, Germany.
Biomark Med. 2009 Oct;3(5):465-81. doi: 10.2217/bmm.09.47.
B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide have emerged as powerful biomarkers for heart failure and other cardiovascular conditions. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are synthesized on the basis of myocardial stress and hypertrophy and are detectable in serum by several commercially available assays. Although both markers display wide similarities in their predictive values for acute and chronic heart failure, important differences exist regarding cutoff values and influence of noncardiac variables. The similarities and differences between B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide will be reviewed and illustrated in detail regarding preanalytics and analytics, predictive properties for acute and chronic heart failure and prognosis as well as the influence of noncardiac parameters.
B 型利钠肽和氨基末端 B 型利钠肽前体已成为心力衰竭和其他心血管疾病的有力生物标志物。B 型利钠肽和氨基末端 B 型利钠肽前体是基于心肌应激和肥大合成的,可以通过几种商业上可用的检测方法在血清中检测到。尽管这两种标志物在预测急性和慢性心力衰竭方面具有广泛的相似性,但在临界值和非心脏变量的影响方面存在重要差异。本文将详细回顾和比较 B 型利钠肽和氨基末端 B 型利钠肽前体之间的相似性和差异,包括分析前和分析、急性和慢性心力衰竭的预测特性以及预后,以及非心脏参数的影响。